BIONANO GENOMICS INC
BNGONASDAQTrading Snapshot
- Day Range
- $1.70 β $1.75
- 52-Week Range
- $1.00 β $2.23
- Volume
- $2.01B
- Avg Volume
- $2.10B
- Shares Outstanding
- 11.5M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $29M
- Last Q Revenue
- $8M
- P/E Ratio
- -0.5
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-2.79
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +475.8%
Why Investors Own BNGO
- βHigh-growth profile β revenue up +47.1% YoY with expanding US Equity exposure.
- βHealthy economics β 61% gross margin and 11% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIONANO GENOMICS INC
BNGOAbout BIONANO GENOMICS INC
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
BIONANO GENOMICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift BNGO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
BIONANO GENOMICS INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.